Our findings provide novel insights that support the development of PRX-targeted inhibitors as radiosensitizers and further exploration of ERK and CREB-1 as potential targets for therapeutic agents against NSCLC. This evidence concerns the gene CREB1 and non-small cell lung carcinoma.